joe wyse ip toolbox in canntech

Dr. Joe I. WyseHead of Patent Dept.

Monetizing Medical Cannabis with the IP Toolbox

$250M

<$100M>

70M$70M

$40M

OTHERS (that we know..)

<$60M

© Proprietary & Confidential

6Major Medical Cannabis companies


7

G.W.Pharma

GW Pharmaceuticals 1998 listed on the NASDAQ Global Market (GWPH) and London Stock Exchange. Product portfolio: cannabinoid prescription Sativex® Oromucosal Spray & Epidiolex® for childhood epilepsy.


8


9

”Our intellectual property portfolio at September 30, 2015, includes 60 patent families with issued and/or pending claims directed to:• Plants• Plant extracts• extraction technology• pharmaceutical formulations• drug delivery • therapeutic uses of cannabinoids, • plant variety rights• know-how & trade secrets.

IP portfolio comprises 53 pending patent applications worldwide. We seek patent protection for the technology, trademarks, trade secrets, know-how ”.Approx. cost of Patents : <<10 million USD

Form 20-FAnnual Report for Foreign Private IssuersFiled Dec 7, 2015, GW Pharma

GW’s multi-dimensional patents portfolio


10

Proactive IP portfolio:1. Proactive technology protection: having a multi-

dimensional defensive patents portfolio.

2. Proactive market dominance: a. having a multi-dimensional offensive patents

portfolio;b. acquiring IP dominancy in relevant* territories.

3. Effective IP-TOOLBOX-inga. Integrating technology protection; utility patents,

design patents & utility models-patents; b. Integrating trade-dress protection: patents,

copyrights & trademarks. * Relevant to both strategic partners (e.g., big pharma) & competitors.


11

OFFENSIVE Utility PATENTS



12

A pharmaceutical formulation for use in administration of cannabinoids via a mucosal surface, the formulation comprising tetrahydrocannabinol (THC) and cannabidiol (CBD) and a matrix comprising at least one agent which is both a self-emulsifier and a cannabinoid solubilizer,said agent when hydrated forming an emulsion containing said THC and CBD which is capable of adhering reversibly to a mucosal surface and allowing controlled release of the THC and CBD.

US6730330 2004/05/04

EXTENDING Formulation Protections


13

A liquid pharmaceutical formulation, for use in the administration of a lipophilic medicament via a mucosal surface, comprising: at least one lipophilic medicament, a solvent and co-solvent, wherein the total amount of solvent and co-solvent present in the formulation is greater than 55% wt/wt of the formulation, the formulation is absent of a self emulsifying agent and a fluorinated propellant, and the formulation has a water content of less than 5% and the formulation is packaged for delivery as a spray, wherein the lipophilic medicament comprises tetrahydrocannabinol (THC) and cannabidiol (CBD), wherein the lipophilic medicament is at least one extract from at least one cannabis plant, and wherein the extract from at least one cannabis plant is a botanical drug substance.

US7709536 2010/05/04EXTENDING Formulation Protections


14

8,790,719 July 29, 2014

A method of treating a human suffering from a glioma consisting essentially of administering therapeutically effective amounts of isolated or highly purified tetrahydrocannabinol and cannabidiol, together with temozolomide to said human to treat said glioma in said human.


15

Integrating Utility PATENTS with Design

PATENTS



16


17

Integrating Utility PATENTS with Trademarks



18The Viagra patent expired in 2012


19

Integrating Utility PATENTS with Plant Breeders

Rights



20

Patents:Protects: Invention (new gene, breeding process), plants

with the inventive feature are protected.Suitable for: Biotechnology, complex traits, new breeding

processes.

Plant Breeder’s Rights (PBR):Protects: New variety described by all its phenotypical

characteristics. Suitable for: Traditional breedingNot suitable for: protection of new genes, traits, breeding

processes. But note Essentially Derived Varieties

(E.D.V.) !!!

Confidential 2013

All Rights Reserved

joe wyse ip toolbox in canntech

Documents